Predictive Talent Dynamics, CDMO JULY 23August 25, 2023
Hopefully some good news on the horizon.
While BioPharma layoffs in 2023 have been a common occurrence, companies with promising pipelines and sufficient funding continue to prosper. Many are capitalising on the diminishing valuations of some companies and actively pursuing M&A deals, which have rebounded in 2023, due to an upcoming patent cliff from 2026 to 2029, pricing pressure from the U.S. Inflation Reduction Act and lower equity valuations.
While the Biopharma market faced challenges with layoffs in 2023, the industry witnessed significant job growth beforehand, and shows signs of returning.
From a recent survey, Approximately, 90% of surveyed Biopharma executives, intend to invest in workforce development and retention in Q4 2023. Attracting and retaining talent remains a fundamental important issue, specifically with AI-related roles in Pharma and Biotech. The trend is especially evident in Big Pharma as companies like Johnson & Johnson, AstraZeneca, Takeda, Novartis and Pfizer actively seek to fill thousands of AI roles. (https://www.drugdiscoverytrends.com/biotech-layoffs-job-openings-2023)
The Biopharma industry had a reduction in job opening growth from Q4 2022 -Q3 2023. At that time, some early stage companies struggled to secure funding, while larger companies adopted caution due to supply chain correction post-Covid. While Biopharma lay-offs continue for smaller companies, positive change is in progress for larger players. The quest for talent has increased, with June 2023 data illustrating a large number of Biopharma job openings, in line with peaks in 2022.
Hiring Demand has accelerated in the last six months and is expected to continue.
Evolution provides elite executive search & headhunting solutions for companies at the forefront of scientific and technological advancement. We provide bespoke recruitment solutions for our exclusive clients on a global level; providing a deeper service provision with value-added services.
Insight into Hiring Trends
The following briefing provides insight to global Bio hiring trends and perceived implications on the future-facing competitive talent pool.Hiring frequency was assessed for all major industry players across biomanufacturing. Data segmented for Manufacturing (CDMO,) Cell and Gene Therapy, Contract Research Organisations (CROs,) Pharma and more general biomanufacturing.
To measure, model and predict ‘supply versus demand’ of Biomanufacturing talent across the global CMO, CGT and Pharma sectors.
Evolution Search Partners; University of Dundee; University College London (UCL.)
To provide analytical strategic intelligence to industry leadership to allow future facing workforce planning, aligned to support capital expansion project decisions, recognising the value of human assets in the economic success of the firm.